Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name	Generic Name	Therapeutic Area	Recommendation Type	Project Status	Date Submission Received	Date Recommendation Issued Sort ascending
Saphris	Asenapine	Bipolar I disorder	List with clinical criteria and/or conditions	Complete	Dec 12, 2011	Jun 14, 2012
Zelboraf	Vemurafenib	Metastatic Melanoma	Reimburse with clinical criteria and/or conditions	Complete	Dec 6, 2011	Jun 1, 2012
Gelnique	Oxybutynin Chloride Gel	Overactive bladder	Do not list	Complete	Oct 25, 2011	May 24, 2012
ASMANEX	Mometasone furoate	Asthma	List	Complete	Nov 10, 2011	May 16, 2012
Sutent	Sunitinib malate	Pancreatic Neuroendocrine Tumour	Reimburse with clinical criteria and/or conditions	Complete	Nov 7, 2011	May 3, 2012
Ozurdex	Dexamethasone intravitreal implant	Macular edema, central retinal vein occlusion	Do not list	Complete	Sep 1, 2011	Apr 25, 2012
Benlysta	Belimumab	Systemic lupus erythematosus	Do not list	Complete	Sep 19, 2011	Apr 25, 2012
RAPAFLO	Silodosin	Benign prostatic hyperplasia	Do not list	Complete	Oct 25, 2011	Apr 19, 2012
Xarelto	Rivaroxaban	Atrial fibrillation, stroke prevention	List with clinical criteria and/or conditions	Complete	Oct 21, 2011	Apr 19, 2012
Visanne	Dienogest	Pain, pelvic pain associated with endometriosis	List with clinical criteria and/or conditions	Complete	Oct 18, 2011	Apr 19, 2012

Last Updated : May 15, 2024